(:SURF)

Aug 31, 2023 04:01 pm ET
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both Institutional Shareholder Services (“ISS”) and...
Aug 29, 2023 12:34 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, AMED, RETA, SURF
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Decibel Therapeutics, Inc. (NASDAQ:...
Aug 29, 2023 11:47 am ET
Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Aug 28, 2023 06:40 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – HT, ABCM, THRN, SURF
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Aug 24, 2023 07:04 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HEP, SCU, SURF
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Holly Energy Partners, L.P. (NYSE:...
Aug 07, 2023 04:09 pm ET
SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Surface Oncology, Inc. (NasdaqGM: SURF) to Coherus BioSciences, Inc. (NasdaqGM: CHRS). Under the terms of the proposed transaction, Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock. Surface shareholders will also receive certain Contingent Value Rights as part of the agreement. KSF is seeking to determine whether this consideration and the process that led to it a
Aug 02, 2023 07:00 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2023. “We...
Aug 01, 2023 12:04 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEWR, SURF, CFMS
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: New Relic, Inc. (NYSE: NEWR)’s sale to...
Aug 01, 2023 11:19 am ET
Moore Kuehn Encourages PACW, NEWR, CFMS, and SURF Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek...
Jul 28, 2023 04:46 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SURF, RETA, INPX
NEW YORK, July 28, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 25, 2023 08:33 am ET
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, CFMS
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Talaris Therapeutics, Inc. (NASDAQ:...
Jun 24, 2023 08:11 pm ET
Lifshitz Law PLLC Announces Investigations of SURF, NETI, NEX, and PTEN
Surface Oncology, Inc. (NASDAQ: SURF) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SURF to Coherus BioSciences, Inc. Under the terms of the agreement, SURF shareholders will...
Jun 22, 2023 01:04 pm ET
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR
NEW YORK, June 22, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 21, 2023 11:22 am ET
SURFACE ONCOLOGY INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Surface Oncology, Inc. (NasdaqGM: SURF) to Coherus BioSciences, Inc. (NasdaqGM: CHRS). Under the terms of the proposed transaction, Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock. Surface shareholders will also receive certain Contingent Value Rights as part of the agreement. KSF is seeking to determine whether this consideration and the process that led to it a
Jun 20, 2023 02:57 pm ET
Moore Kuehn Encourages SURF, NEX, NETI, and DICE Investors to Contact Law Firm
NEW YORK, June 20, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Jun 16, 2023 01:53 pm ET
Shareholder Alert: Ademi LLP investigates whether Surface Oncology, Inc. has obtained a Fair Price in its transaction with Coherus
MILWAUKEE, June 16, 2023 /PRNewswire/ -- Ademi LLP is investigating Surface (Nasdaq: SURF) for possible breaches of fiduciary duty and other violations of law in its transaction with Coherus. 
Jun 16, 2023 01:18 pm ET
Moore Kuehn Encourages NETI, SURF, KDNY, and NEX Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Jun 16, 2023 10:20 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, NETI, SURF
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: NexTier Oilfield Solutions Inc. (NYSE:...
Jun 16, 2023 10:12 am ET
SURF Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surface Oncology, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Surface Oncology, Inc. (NASDAQ: SURF) to Coherus BioSciences, Inc. is fair to Surface shareholders.
Jun 16, 2023 09:31 am ET
Thinking about buying stock in Workhorse Group, Virgin Galactic Holdings, Surface Oncology, Applied Optoelectronics, or Lordstown Motors?
NEW YORK, June 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WKHS, SPCE, SURF, AAOI, and RIDE.
Jun 16, 2023 07:01 am ET
Coherus to Acquire Surface Oncology
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Surface Oncology, Inc. (Surface, Nasdaq: SURF) today announced that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface...
Jun 16, 2023 07:01 am ET
Coherus to Acquire Surface Oncology
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Surface Oncology, Inc. (Surface, Nasdaq: SURF) today announced that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface...
May 04, 2023 07:00 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter 2023, as...
Apr 18, 2023 07:00 am ET
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical data for SRF114, a fully human...
Mar 16, 2023 08:00 am ET
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023 
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present a poster highlighting new preclinical data for SRF114,...
Mar 09, 2023 07:00 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full...
Feb 28, 2023 04:15 pm ET
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a Novel...
Feb 02, 2023 08:00 am ET
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a...
Jan 09, 2023 08:00 am ET
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that its licensee, Surface Oncology...
Jan 05, 2023 07:30 am ET
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the first patient has been dosed in its Phase 1/2 clinical study...
Nov 07, 2022 08:00 am ET
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of two posters at the 2022 Society for Immunotherapy of...
Nov 02, 2022 06:30 am ET
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today provided a corporate update and reported financial results for the third quarter of...
Oct 19, 2022 07:00 am ET
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
VIB, Flanders’ leading life sciences institute, and Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced jointly the publication...
Sep 14, 2022 07:30 am ET
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company will present new preclinical data on the role of IL-27 in...
Sep 07, 2022 04:30 pm ET
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a...
Aug 24, 2022 04:30 pm ET
Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a...
Aug 03, 2022 07:00 am ET
Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and business highlights for the second quarter of 2022 as...
Aug 01, 2022 04:30 pm ET
Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a virtual...
Jun 29, 2022 07:00 am ET
Surface Oncology Appoints Carsten Brunn to Board of Directors
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company’s board of directors. Dr....
Jun 20, 2022 10:05 am ET
Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that findings from a study interrogating the role of the IL-27 pathway in...
Jun 03, 2022 04:30 pm ET
Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company granted non-qualified stock options to two new...
Jun 01, 2022 08:00 am ET
Surface Oncology to Participate in Upcoming Investor Conferences
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in two...
May 26, 2022 05:00 pm ET
Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new clinical data on SRF388, a potential first-in-class...
May 17, 2022 04:30 pm ET
Surface Oncology to Participate in Upcoming Investor Conferences
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in two...
May 09, 2022 08:31 am ET
Thinking about buying stock in Better Therapeutics, Surface Oncology, Redbox Entertainment, Aterian, or Traeger?
NEW YORK, May 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BTTX, SURF, RDBX, ATER, and COOK.
May 09, 2022 07:10 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported financial results and corporate highlights for the first quarter of 2022 as well...
May 06, 2022 04:30 pm ET
Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company granted non-qualified stock options to five new...
Apr 27, 2022 04:15 pm ET
Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will share a clinical update on SRF388 in an oral presentation at...
Apr 21, 2022 04:05 pm ET
Surface Oncology Named one of the 2022 Best Places to Work by Boston Business Journal
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized by the Boston Business Journal as one of the...
Apr 14, 2022 07:30 am ET
Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the initiation of two Phase 2 clinical studies evaluating SRF388, a...
Apr 08, 2022 04:01 pm ET
Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical and translational data for SRF388, a...
Apr 01, 2022 04:42 pm ET
Surface Oncology Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Surface’s board of directors granted Theresa Boni, J.D., general...
Mar 31, 2022 07:30 am ET
Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the first patient has been dosed by GlaxoSmithKline (GSK) in the Phase 1...
Mar 15, 2022 07:30 am ET
Surface Oncology Appoints Theresa Boni as General Counsel
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Theresa Boni, J.D., as general counsel and senior vice...
Mar 02, 2022 07:10 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full...
Feb 28, 2022 04:30 pm ET
Surface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen’s 42nd Annual Health Care Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in the...
Feb 10, 2022 07:00 am ET
Surface Oncology to Participate in Citi's 2022 Virtual Immuno-Oncology Summit
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that company management will participate in a fireside chat during Citi's...
Dec 15, 2021 07:05 am ET
Surface Oncology Appoints Denice Torres as Chair of the Board of Directors
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointments of Denice Torres to chair of the board of directors and...
Dec 06, 2021 09:30 am ET
Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that new data from the ongoing Phase 1 study of SRF617, an antibody...
Dec 03, 2021 07:00 am ET
Surface Oncology Named a 2021 Top Place to Work by the Boston Globe
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company was named one of the Top Places to Work in Massachusetts in 2021 by the...
Dec 02, 2021 07:00 am ET
Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a poster presentation sharing new clinical data from the ongoing...
Dec 01, 2021 07:00 am ET
Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIG
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has cleared the...
Nov 09, 2021 08:10 am ET
Preclinical Data Supporting Therapeutic Potential of Surface Oncology’s Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that two scientific posters sharing updated preclinical data from Surface...
Nov 08, 2021 07:00 am ET
Surface Oncology to Participate in the 2021 Annual Cowen IO Next Summit
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a...
Nov 04, 2021 07:10 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results for the third quarter 2021, and provided a corporate...
Nov 02, 2021 07:00 am ET
Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that scientific posters sharing preclinical data will be presented at...
Oct 04, 2021 07:00 am ET
Surface Oncology Announces New Randomized Phase 2 Clinical Study Evaluating SRF388 in Patients with First-Line Hepatocellular Carcinoma in Clinical Collaboration with Roche
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced details about its plan to initiate a randomized Phase 2 clinical study...
Aug 05, 2021 07:10 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2021, and...
Jul 08, 2021 07:00 am ET
Surface Oncology Appoints Denice Torres to Board of Directors
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Denice Torres will join the company’s board of directors. Ms. Torres...
Jun 04, 2021 07:05 am ET
SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in Data Presented at American Society of Clinical Oncology Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new data from the ongoing Phase 1 studies of SRF388...
Jun 04, 2021 07:00 am ET
Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naïve Hepatocellular Carcinom
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced a clinical trial collaboration with Roche to evaluate SRF388, Surface’s...
May 05, 2021 06:45 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter 2021, as...
Apr 28, 2021 04:05 pm ET
Surface Oncology to Present Clinical Updates for SRF388 and SRF617
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a scientific poster sharing clinical data from its Phase 1 study of...
Apr 27, 2021 07:00 am ET
Surface Oncology Expands Leadership Team with Key Executive Appointment and Promotions
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today the appointment of Henry Rath as chief business officer, and the promotions...
Apr 19, 2021 07:00 am ET
Surface Oncology Named a 2021 Best Places to Work Company by Boston Business Journal
Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized by the Boston Business Journal as one of the Best Places to...
Apr 09, 2021 07:53 am ET
Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, will present preclinical findings supporting the company’s lead product programs, SRF388...
Mar 30, 2021 04:30 pm ET
Surface Oncology’s SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
Mar 10, 2021 04:35 pm ET
Surface Oncology to Present Preclinical Data for Lead Product Programs at the American Association for Cancer Research Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced two scientific e-posters sharing updated preclinical data will be presented...
Mar 09, 2021 07:01 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full year...
Mar 09, 2021 07:00 am ET
Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck, known as MSD...
Feb 24, 2021 07:00 am ET
Surface Oncology to Participate in Upcoming March Investor Conferences
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor microenvironment, today announced that Rob Ross, M.D., incoming chief executive officer, will participate in the...
Feb 23, 2021 08:31 am ET
Thinking about buying stock in SCYNEXIS, Surface Oncology, Callon Petroleum, Petroleo Brasileiro, or Melco Resorts & Entertainment?
NEW YORK, Feb. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SCYX, SURF, CPE, PBR, and MLCO.
Feb 11, 2021 07:00 am ET
Surface Oncology to Appoint Robert Ross, M.D., as President and Chief Executive Officer
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor microenvironment, announced today that Robert Ross, M.D., who has served as chief medical officer at Surface Oncology...
Jan 19, 2021 08:31 am ET
Thinking about buying stock in Gevo, Applied DNA Sciences, Surface Oncology, Aldeyra Therapeutics, or BioNano Genomics?
NEW YORK, Jan. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEVO, APDN, SURF, ALDX, and BNGO.
Jan 11, 2021 06:00 am ET
Surface Oncology to Participate in H.C. Wainwright Bioconnect 2021 Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, will participate in the upcoming...
Dec 30, 2020 07:30 am ET
Thinking about buying stock in Hepion Pharmaceuticals, BioNano Genomics, T2 Biosystems, Surface Oncology, or Sesen Bio?
NEW YORK, Dec. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HEPA, BNGO, TTOO, SURF, and SESN.
Dec 18, 2020 07:30 am ET
Thinking about buying stock in CNS Pharmaceuticals, DermTech, Ampio Pharmaceuticals, Surface Oncology, or Amyris?
NEW YORK, Dec. 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNSP, DMTK, AMPE, SURF, and AMRS.
Dec 17, 2020 06:55 am ET
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program
Surface Oncology (Nasdaq: SURF) today announced an agreement for GSK to exclusively license worldwide development and commercial rights to Surface Oncology’s preclinical program SRF813, a fully human IgG1 antibody targeting PVRIG (also known as...
Nov 25, 2020 07:00 am ET
Surface Oncology to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Robert Ross, M.D., chief...
Nov 13, 2020 07:05 am ET
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both of its lead clinical programs, SRF617 (targeting CD39) and SRF388...
Nov 11, 2020 08:31 am ET
Thinking about buying stock in Surface Oncology, Northern Oil & Gas, Co-Diagnostics, Howmet Aerospace, or Aptevo Therapeutics?
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SURF, NOG, CODX, HWM, and APVO.
Nov 11, 2020 07:00 am ET
Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Nov 10, 2020 06:20 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the third quarter 2020, as...
Nov 09, 2020 04:24 pm ET
Surface Oncology to Present at the Cowen IO Next Summit
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its...
Nov 09, 2020 09:00 am ET
Surface Oncology to Present SRF388 and SRF114 Preclinical Data at the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that preclinical data on SRF388, a first in class IL-27 blocking antibody...
Oct 26, 2020 04:05 pm ET
Surface Oncology to Report SRF388 Preclinical Data at the Upcoming International Cytokine and Interferon Society’s Cytokines 2020 Virtual Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that preclinical data on SRF388, a first in class IL-27 blocking antibody...
Sep 16, 2020 05:05 pm ET
Surface Oncology to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its...
Sep 11, 2020 03:00 pm ET
Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference
Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its...
Sep 09, 2020 01:15 pm ET
Surface Oncology to Present at the Baird Global Healthcare Conference
Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its...
Aug 11, 2020 06:30 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2020, as...
Aug 05, 2020 11:59 am ET
Surface Oncology to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, will present at the upcoming...
May 28, 2020 04:10 pm ET
Surface Oncology Announces Change to Location and Format of 2020 Annual Meeting of Stockholders
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its 2020 Annual Meeting of Stockholders has been changed to a virtual...
May 22, 2020 09:31 am ET
Thinking about buying stock in Tetraphase Pharmaceuticals, Surface Oncology, L Brands, Tilray, or Bridgeline Digital?
NEW YORK, May 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTPH, SURF, LB, TLRY, and BLIN.
May 20, 2020 09:31 am ET
Thinking about buying stock in Surface Oncology, Inovio Pharmaceuticals, American Airlines, Altimmune, or Aurora Cannabis?
NEW YORK, May 20, 2020  InvestorsObserver issues critical PriceWatch Alerts for SURF, INO, AAL, ALT, and ACB.
May 20, 2020 07:15 am ET
Surface Oncology Fully Utilizes its $30M At-the-Market Facility
Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today that it has raised gross proceeds of approximately $28.9 million through...
May 20, 2020 07:05 am ET
Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck (NYSE: MRK),...
May 15, 2020 07:30 am ET
Surface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced five scientific posters sharing updated preclinical data at the American...
May 14, 2020 07:30 am ET
Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully human, high-affinity...
May 13, 2020 08:00 am ET
Surface Oncology to Present at the UBS Virtual Global Healthcare Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its chief executive officer, Jeff Goater, will present at the upcoming...
May 12, 2020 06:20 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter 2020, as...
Apr 23, 2020 08:00 am ET
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has initiated a Phase 1 clinical trial of its first-in-class...
Mar 17, 2020 08:00 am ET
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has initiated a Phase 1/1b clinical trial of its antibody candidate...
Mar 10, 2020 06:20 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2019
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full...
Feb 25, 2020 04:05 pm ET
Surface Oncology to Present at the 40th Annual Cowen Healthcare Conference
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Robert Ross, M.D., chief...
Jan 27, 2020 04:05 pm ET
Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational...
Dec 09, 2019 05:45 pm ET
Notice to Shareholders of Surface Oncology, Inc. (NASDAQ: SURF) Regarding Dismissal of Putative Investor Class Action
This Notice, which has been authorized by the Supreme Court of the State of New York, County of New York, relates to the requested dismissal without prejudice of the putative class action captioned Ang v. Surface Oncology, Inc. et al., Index No. 655304/2019 (the “Action”).
Nov 26, 2019 08:00 am ET
Surface Oncology to Present at Evercore ISI 2nd Annual HealthCONx Conference
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D., chief...
Nov 25, 2019 08:00 am ET
Surface Oncology Announces $25 Million Debt Financing from K2 HealthVentures
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced it has secured a debt financing facility for up to $25 million from K2...
Nov 18, 2019 06:30 am ET
Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has submitted an Investigational New Drug (IND) application to the...
Nov 12, 2019 06:30 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2019
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the third quarter of 2019....
Nov 07, 2019 08:00 am ET
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present at the Society for the Immunotherapy of Cancer’s...
Oct 07, 2019 07:00 am ET
Surface Oncology to Host Analyst and Investor Day on November 18, 2019 in New York City
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company will host its inaugural Analyst and Investor Day on...
Sep 03, 2019 04:05 pm ET
Surface Oncology to Present at the Baird 2019 Global Healthcare Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D.,...
Sep 03, 2019 07:00 am ET
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
Surface Oncology (NASDAQ:SURF), today announced Ramy Ibrahim, M.D., will join the company’s board of directors. Dr. Ibrahim is a medical oncologist currently serving as chief medical officer and vice president of clinical development at the Parker...
Aug 28, 2019 10:45 am ET
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, Inc. (“Surface” or “the Company”) (NASDAQ: SURF) for false and misleading SEC filings. If you...
Aug 27, 2019 08:00 am ET
Bragar Eagel & Squire, P.C. is Investigating Casa Systems, Greenlane Holdings, Surface Oncology, and Sunnova Energy on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Casa Systems, Inc. (NASDAQ: CASA), Greenlane Holdings, Inc. (NASDAQ: GNLN), Surface Oncology, Inc. (NASDAQ: SURF), and Sunnova Energy International, Inc. (NYSE: NOVA) on behalf...
Aug 14, 2019 08:55 pm ET
Bragar Eagel & Squire, P.C. is Investigating Casa Systems, Greenlane Holdings, Surface Oncology, and Pintec Technology on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Casa Systems, Inc. (NASDAQ: CASA), Greenlane Holdings, Inc. (NASDAQ: GNLN), Surface Oncology, Inc. (NASDAQ: SURF), and Pintec Technology Holdings, Ltd. (NASDAQ: PT) on behalf of...
Aug 07, 2019 09:30 pm ET
Bragar Eagel & Squire, P.C. is Investigating Greenlane Holdings, Surface Oncology, and Pintec Technology on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Greenlane Holdings, Inc. (NASDAQ: GNLN), Surface Oncology, Inc. (NASDAQ: SURF), and Pintec Technology Holdings, Ltd. (NASDAQ: PT) on behalf of investors. More information about...
Aug 07, 2019 10:07 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, Inc. (“Surface” or “the Company”) (NASDAQ: SURF) for false and misleading SEC filings. If you...
Aug 07, 2019 06:05 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2019
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter of 2019....
Aug 06, 2019 05:52 pm ET
Shareholder Alert: Robbins Arroyo LLP is Investigating Surface Oncology, Inc. (SURF)
Shareholder rights law firm Robbins Arroyo LLP informs shareholders that it is investigating Surface Oncology (NASDAQ: SURF) for potential violations of federal securities laws pursuant to its April 2018 initial public offering ("IPO"). Surface Oncology completed its IPO on April 23, 2018, offering shares at $15.00. Since its IPO, Sur
Aug 06, 2019 12:55 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, Inc. (“Surface” or “the Company”) (NASDAQ:
Aug 03, 2019 11:05 am ET
Shareholder Rights Law Firm Johnson Fistel Launches Investigations
SAN DIEGO, Aug. 3, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims for violations of federal law against the following companies that recently issued stock in connection with an initial public offering ("IPO"):
Jul 26, 2019 11:40 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, Inc. (“Surface” or “the Company”) (NASDAQ:
Jun 07, 2019 12:00 pm ET
Surface Oncology to Participate in 40th Annual Goldman Sachs Global Healthcare Conference
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Jeff Goater, chief executive officer, will participate in the Goldman...
May 24, 2019 06:00 am ET
Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment (TME), today announced the presentation of updated preclinical findings regarding the...
May 15, 2019 04:00 pm ET
Surface Oncology to Present at Two Upcoming Healthcare Conferences
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Jeff Goater, chief executive officer, will be participating and presenting a...
May 09, 2019 07:00 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2019
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter of 2019....
Apr 24, 2019 07:00 am ET
Surface Oncology Management to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, will be participating and...
Apr 01, 2019 07:00 am ET
Surface Oncology Announces Appointment of Wendy Dwyer as Chief Business Officer
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Wendy Dwyer as chief business officer. Ms. Dwyer will be...
Mar 07, 2019 04:01 pm ET
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2018
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full...
Mar 04, 2019 07:00 am ET
Surface Oncology to Present at the 39th Annual Cowen Healthcare Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, will provide a corporate update...
Feb 04, 2019 04:21 pm ET
Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388
Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the retention of worldwide rights for its novel antibody, SRF388, targeting...
Jan 16, 2019 04:50 pm ET
Publication in ImmunoHorizons Highlights the Role of IL-27 in Upregulation of Multiple Checkpoint Proteins
Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today highlights the publication of a paper describing the biological activity of IL-27, an...
Jan 04, 2019 07:00 am ET
Surface Oncology Announces Appointment of F. Stephen Hodi, MD to its Scientific Advisory Board
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of the F. Stephen Hodi, MD to the company’s scientific...
Dec 21, 2018 07:00 am ET
Surface Oncology Added to the NASDAQ Biotechnology Index
Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today that it has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI)....
Dec 18, 2018 04:01 pm ET
Surface Oncology Resets Portfolio Priorities, Extends Cash Runway Through 2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today updates related to its product pipeline, notably the significant reduction...
Dec 17, 2018 07:00 am ET
Surface Oncology Promotes Jessica Fees to Senior Vice President, Finance and Business Operations
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning the promotion of Jessica Fees to senior vice president, finance and...
Nov 20, 2018 07:00 am ET
Surface Oncology Announces Upcoming Investor Presentations
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning that it will host presentations at two investor conferences in the...
Nov 13, 2018 06:30 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2018
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the third quarter of 2018....
Aug 30, 2018 09:59 am ET
Surface Oncology to Present at the Baird 2018 Global Healthcare Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D.,...
Aug 14, 2018 07:00 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2018
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter of 2018....
Jul 30, 2018 02:24 pm ET
FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma
Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...
Jun 21, 2018 07:00 am ET
Surface Oncology Recognized as one of the “Best Places to Work” by Boston Business Journal
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized as one of the Best Places to Work in 2018 by the...
Jun 12, 2018 07:00 am ET
Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the initiation of a Phase I trial of SRF373, a fully human antibody...
Jun 11, 2018 05:07 pm ET
Surface Oncology to be Added to the Russell 3000 Index and Russell 2000 Index
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will join the small-cap Russell 2000 index at the conclusion of the...
Jun 08, 2018 07:10 am ET
Surface Oncology to Present at Goldman Sachs 39th Annual Global Healthcare Conference
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Chief Executive Officer Jeff Goater will present at the Goldman Sachs...
May 29, 2018 05:00 pm ET
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2018
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter of 2018....
May 15, 2018 04:01 pm ET
Surface Oncology to Present at 2018 UBS Global Healthcare Conference
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Chief Executive Officer Jeff Goater will present a company overview at...
Apr 23, 2018 04:30 pm ET
Surface Oncology Announces Closing of $119.5 Million Aggregate Financing, Consisting of $108.0 Million Initial Public Offering and $11.5 Million Concurrent Private Placement
CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (“Surface”), an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment, today announced the closing of its initial public offering of 7,200,000 shares of common...
Apr 18, 2018 09:00 pm ET
Surface Oncology Announces $119.5 Million Aggregate Financing, Consisting of $108.0 Million Initial Public Offering and $11.5 Million Concurrent Private Placement
CAMBRIDGE, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (“Surface”) (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment, today announced the pricing of its initial public offering of 7,200,000 shares...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.